Toggle menu

TPTIH

Start date:
August 2015
End date:
Predicted September 2017
Co-ordinated by:
The University of Nottingham

To establish genetic associations between patients with thiazide-induced hyponatraemia and patients taking a thiazide who did not develop hyponatraemia.

Eligibility criteria

Inclusion criteria:

  • Age 18-100 years
  • Have the capacity to give informed consent
  • Be taking a thiazide or thiazide-related diuretic unless in the non-thiazide control group
  • Plasma sodium concentration of less than 130 mM for cases and between 135 mM and 145 mM for controls

Local PI

Dr Ann Lockman

Consultant in Acute Medicine

Research Team

Julia Grahamslaw

Lead Research Nurse

Caroline Blackstock

AMU Senior Research Nurse

Bev Goldberg

AMU Senior Research Nurse

Rachel O'Brien

Lead Research Nurse

More EMERGE Trials

The RECOVERY Trial

Randomised Evaluation of COVID-19 Therapy

The purpose of this study is to test a new vaccine, ChAdOx1 nCoV-19, against COVID-19 in healthy volunteers.

The ChAdOx1 nCoV-19 vaccine has been developed in Oxford in an effort to protect healthy people from the pandemic. This study will evaluate the safety of the vaccine and its ability to generate an immune response against the virus.  

This is a randomised trial. Participants will be randomly allocated to receive either the ChAdOx1 nCoV-19 vaccine, or a Men ACWY (meningitus vaccine). Volunteers will not be told which vaccine they will receive.

Participants will be asked to return for 6 visits across 12 months to evaluate their health.

Across the UK the trial aims to recruit 10,260 volunteers.

If you are interested in taking part, please click on this link and complete the online questionnaire: https://www.covid19vaccinetrial.co.uk/participate-edinburgh

Read more

COV_002 Vaccine Trial

The purpose of this study is to test a new vaccine against COVID-19 in healthy volunteers.